
    
      The observational study began on 01 November 2012 and is scheduled for a period of 10 years
      continued (until 01 November 2022). The duration of the observational study for each patient
      is not fixed corresponding to the character of a non-interventional study. According to the
      underlying disease, characterized either acute or chronic, there are 2 and 3 observations
      within the treatment period, respectively. Documentation comprises the course of the
      underlying diseases (by tracking of general and diseases-specific symptoms), drug
      compatibility (by ADR assessment), concomitant medication or other treatment, health economic
      data, details of treatment regimen and standard epidemiological data.
    
  